Precigen secures up to $125M non-dilutive senior secured loan financing from Pharmakon

PRECIGEN, INC.

$100M funded at close; $25M delayed draw available through June 2027; matures Sept 2030.
Interest at three-month SOFR (3.75% floor) + 6.50%, payable quarterly; amortization begins Sept 2028.
Proceeds to support U.S. commercialization of PAPZIMEOS and potential expansion into international and pediatric indications.
Loan is senior secured by substantially all U.S. assets, including IP; customary covenants and events of default.
CFO states strengthening balance sheet provides financial flexibility as company enters projected significant growth period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.